|
ARTIST |
‘ARTIST’ stands for a translational research Approach to development of optimal Renal cancer Treatments In Surgical and systemic Therapy patients, a single-centre translational research study designed to identify and characterize novel biomarkers for the optimal detection, monitoring and treatment of renal cell cancer (RCC). |
Dr James Jones |
31 Dec 2025 |
4 Jan 2021 |
Kidney |
|
BEAT-meso |
A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma |
Dr David Gilligan |
15 Jan 2025 |
5 Sep 2019 |
Lung |
|
Best-Of |
Phase III study assessing the "Best-Of" radiotherapy compared to the "Best-Of" surgery (trans-oral surgery (TOS) in patients with T1-T2, N0 oropharyngeal carcinoma |
Dr Ekpemi Irune |
1 Jan 2026 |
17 Nov 2020 |
Head & neck |
|
CompARE Trial |
Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer |
Dr Rashmi Jadon |
31 Jan 2026 |
5 Mar 2019 |
Head & neck |
|
COSI |
An International Randomised Clinical Trial of Therapeutic Interventions with the Potential to Improve Outcome in Adults with Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation |
Dr Charles Crawley |
1 Apr 2025 |
9 Sep 2020 |
Haematological |
|
COSMIC-313 |
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk |
Dr Kate Fife |
1 Mar 2025 |
6 Dec 2019 |
Kidney |
|
EMBRACE-II |
Image guided intensity modulated External beam radiochemotherapy and MRI based adaptive BRAchytherapy in locally advanced CErvical cancer |
Dr Li Tee Tan |
30 Jun 2024 |
7 Nov 2017 |
Gynaecological |
|
FLAURA-2 |
A phase III, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non-small cell lung cancer (FLAURA-2) |
Dr Gary Doherty |
23 Mar 2026 |
25 Sep 2020 |
Lung |
|
KEYNOTE-641 |
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Dr Danish Mazhar |
30 Apr 2024 |
8 Oct 2019 |
Prostate |
|
LEAP-006 |
A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006) |
Dr Gary Doherty |
30 Sep 2024 |
18 Sep 2020 |
Lung |
|
MITRE |
Microbiome Immunotherapy Toxicity and Response Evaluation (MITRE) An observational study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy |
Dr Pippa Corrie |
8 Jul 2025 |
30 Mar 2021 |
Lung, Kidney, Skin & melanoma |
|
PACE-C |
International randomised study of prostatectomy vs stereotactic body radiotherapy (SBRT) and conventional radiotherapy vs SBRT for organ-confined prostate cancer |
Dr Alex Martin |
26 Apr 2026 |
5 Feb 2020 |
Prostate |
|
Pharmacyclics PCYC 1141 (Bruton's Tyrosine Kinase Inhibitor, Treatment for Follicular Lymphoma) |
A Multicentre, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma |
Dr George Follows |
16 Mar 2025 |
27 Jul 2018 |
Haematological |
|
RAMPART |
Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage multi-centre randomised-controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse |
Dr Sarah Welsh |
31 Dec 2023 |
20 Jul 2018 |
Kidney |
|
ROAM |
Radiation versus observation following surgical resection of atypical meningioma: A randomised controlled trial |
Dr Sarah Jefferies |
30 Apr 2025 |
17 Nov 2016 |
Brain and CNS |
|
SKYSCRAPER-07 |
A phase III randomised , double-blind, placebo-controlled study of Atezolizumab with or without Tiragolumab (anti-tigit antibody) in patients with locally advanced esophageal squamous cell carcinoma |
Dr Lizzie Smyth |
31 Dec 2025 |
17 Nov 2020 |
Oesophageal |
|
WIRE |
‘WIRE’ stands for WIndow-of-opportunity clinical trial platform for evaluation of novel treatment strategies in REnal cell cancer, a clinical trial that makes opportunistic investigational use of the existing 4-week surgical window-of-opportunity between the decision to operate on surgically resectable renal cell cancer (RCC) and surgery itself. |
Professor Grant Stewart |
31 Jan 2025 |
28 Aug 2020 |
Kidney |
